NeuroSense Buys Time on Nasdaq, but Can a $13 Million Biotech Close a $35 Million Gap Before the Clock Runs Out?

Shares of NeuroSense Therapeutics surged 13.2% to $3.95 after the company disclosed that a Nasdaq Hearings Panel will review its delisting appeal on November 10, 2026. The rally signals investor relief that the stock keeps trading for now — but the math behind the company's survival on the exchange remains daunting, and the hearing's outcome is far from guaranteed.

• The Stock Stays Listed — for Now — but the Real Hurdle Is Market Value, Not Share Price. NeuroSense has already regained compliance with Nasdaq's $1.00 minimum bid-price rule. That was the easy part. The only remaining deficiency is Nasdaq's $35 million minimum market value of listed securities requirement.

As of recently, NRSN's market capitalization sits around $13 million — barely a third of the threshold. Even after today's pop, the gap is enormous. Closing it requires either a sustained stock price roughly triple current levels or a significant share issuance — which itself would dilute existing holders.

• The Company Has Almost No Cash to Fund the Fight. NeuroSense held just $166,000 in cash as of the latest quarter, with negative working capital of $1.74 million and negative book value. That leaves almost zero margin for error and makes the company dependent on external financing at a moment when its bargaining position is weakest.

• A Canadian Drug Filing and a Phase 3 Grant Decision Could Change the Story — or Not. NeuroSense is targeting a December 2026 regulatory submission to Health Canada for its ALS therapy , and a Q1 2027 decision on potential non-dilutive grant funding for its Phase 3 trial . Phase 2b data showed a 65% reduction in risk of death and a greater-than-14-month survival benefit — promising science that was published in JAMA Neurology. But clinical promise doesn't pay bills. Without the grant or a partner, financing a large late-stage trial on a micro-cap balance sheet is essentially impossible.

• The Panel Can Say No, and History Suggests It Might. The Nasdaq panel may grant an exception of up to 180 days but could also deny the appeal outright; the company itself acknowledges there is no assurance it will regain or maintain compliance. A rejection would trigger delisting to the over-the-counter market, slashing liquidity and institutional interest in a stock that already has only 1.12% institutional ownership.

Today's rally is a bet on survival, not on value. The November 10 hearing will determine whether NeuroSense gets one more window — or runs out of runway.